Neurotech International Ltd. (AU:NTI) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Neurotech International Ltd. has received ethics approval to begin a pharmacokinetic study of its NTI164 drug in healthy adults, an important step for regulatory compliance in both the U.S. and Australia. The study aims to provide critical data on the drug’s metabolism and excretion, supporting its development for treating neurological disorders. Investors may find this development promising as the company advances its clinical trials and regulatory efforts.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.